Order Summary

In order to access content on the Celltelligence Library, you must have an account.

The price for access is $0.00.

Do you have a discount code? Click here to enter your discount code.

Account Information Already have an account? Log in here


By selecting this, I agree to receive emails from celltelligence.com.

You will be granted access to your Celltelligence Library to view the full article after sign up.

Gilead Reports Outstanding Cell Therapy Revenue Growth; Yescarta's Manufacturing Capacity Scaled to Address Demand; Updated Regulatory Milestones for Yescarta and Tecartus in the EU; Gilead’s Q2 2022 Earnings Call Summary

Here is a brief preview of this blast: On Tuesday, August 2, Gilead (Kite) held their Q2 2022 earnings call (press release / presentation) highlighting an increase in revenue for their cell therapy franchise, while discussing EU regulatory milestones for Yescarta and Tecartus (CD19 CAR-Ts). Below, Celltelligence provides insights on Gilead’s cell therapy revenue increase, while discussing how Gilead’s manufacturing strategy could accommodate Yescarta’s expected increase in demand.

About The Author

The Celltelligence Team

Content Leads & Contributors
The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.